Difficult-to-treat pediatric obsessive-compulsive disorder: Feasibility and preliminary results of a randomized pilot trial of D-cycloserine-augmented behavior therapy
dc.contributor.author | Farrell, L. | |
dc.contributor.author | Waters, A. | |
dc.contributor.author | Boschen, M. | |
dc.contributor.author | Hattingh, Laetitia | |
dc.contributor.author | McConnell, H. | |
dc.contributor.author | Milliner, E. | |
dc.contributor.author | Collings, N. | |
dc.contributor.author | Zimmer-Gembeck, M. | |
dc.contributor.author | Shelton, D. | |
dc.contributor.author | Ollendick, T. | |
dc.contributor.author | Testa, C. | |
dc.contributor.author | Storch, E. | |
dc.date.accessioned | 2017-01-30T14:23:14Z | |
dc.date.available | 2017-01-30T14:23:14Z | |
dc.date.created | 2014-01-20T20:01:14Z | |
dc.date.issued | 2013 | |
dc.identifier.citation | Farrell, Lara J. and Waters, Allison M. and Boschen, Mark J. and Hattingh, Laetitia and McConnell, Harry and Milliner, Ella L. and Collings, Nigel and Zimmer-Gembeck, Melanie and Shelton, Doug and Ollendick, Thomas H. and Testa, Chris and Storch, Eric A. 2013. Difficult-to-treat pediatric obsessive-compulsive disorder: Feasibility and preliminary results of a randomized pilot trial of D-cycloserine-augmented behavior therapy. Depression and Anxiety. 30 (8): pp. 723-731. | |
dc.identifier.uri | http://hdl.handle.net/20.500.11937/38575 | |
dc.identifier.doi | 10.1002/da.22132 | |
dc.description.abstract |
Background: This study examined the feasibility and preliminary effectiveness of d-cycloserine (DCS)–augmented cognitive behavioral therapy (CBT) for children and adolescents with difficult-to-treat Obsessive Compulsive Disorder, in a double-blind randomized controlled pilot trial (RCT).Methods: Seventeen children and adolescents (aged 8–18 years) with a primary diagnosis of OCD, which was deemed difficult-to-treat, were randomly assigned to either nine sessions of CBT including five sessions of DCS-augmented exposure and response prevention (ERP) [ERP + DCS] or nine sessions of CBT including five sessions of placebo-augmented ERP [ERP + PBO]. Weight-dependent DCS or placebo doses (25 or 50 mg) were taken 1 hour before ERP sessions.Results: At post treatment, both groups showed significant improvements with 94% of the entire sample classified as responders. However, a greater improvement in the ERP + DCS relative to the ERP + PBO condition was observed at 1-month follow-up on clinician-rated obsessional severity and diagnostic severity, and parent ratings of OCD severity. There were no changes across time or condition from 1- to 3-month follow-up.Conclusions: In this preliminary study, DCS-augmented ERP produced significant improvements in OCD severity from posttreatment to 1-month follow-up, relative to a placebo control condition, in severe and difficult-to-treat pediatric OCD. The significant effect on obsessional severity suggests that DCS augmentation might be associated with enhanced modification of obsessional thoughts during ERP, and warrants further investigation. | |
dc.publisher | Wiley-Liss, Inc | |
dc.title | Difficult-to-treat pediatric obsessive-compulsive disorder: Feasibility and preliminary results of a randomized pilot trial of D-cycloserine-augmented behavior therapy | |
dc.type | Journal Article | |
dcterms.source.volume | 30 | |
dcterms.source.startPage | 723 | |
dcterms.source.endPage | 731 | |
dcterms.source.issn | 1091-4269 | |
dcterms.source.title | Depression and Anxiety | |
curtin.note |
This is the accepted version of the following article: Farrell, Lara J. and Waters, Allison M. and Boschen, Mark J. and Hattingh, Laetitia et. al., 2013. Difficult-to-treat pediatric obsessive-compulsive disorder: Feasibility and preliminary results of a randomized pilot trial of D-cycloserine-augmented behavior therapy. Depression and Anxiety. 30 (8): pp. 723-731, which has been published in final form at | |
curtin.department | ||
curtin.accessStatus | Open access |